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Abstract
Background: Sarcoidosis is a polygenic disease with diverse phenotypic presentations characterized by an abnormal
antigen-mediated Th1 type immune response. At present, progress towards understanding sarcoidosis disease mechanisms
and the development of novel treatments is limited by constraints attendant to conducting human research in a rare
disease in the absence of relevant animal models. We sought to develop a computational model to enhance our
understanding of the pathological mechanisms of and predict potential treatments of sarcoidosis.
Methodology/Results: Based upon the literature, we developed a computational model of known interactions between
essential immune cells (antigen-presenting macrophages, effector and regulatory T cells) and cytokine mediators (IL-2,
TNFa, IFNc) of granulomatous inflammation during sarcoidosis. The dynamics of these interactions are described by a set of
ordinary differential equations. The model predicts bistable switching behavior which is consistent with normal (self-limited)
and ‘‘sarcoidosis-like’’ (sustained) activation of the inflammatory components of the system following a single antigen
challenge. By perturbing the influence of model components using inhibitors of the cytokine mediators, distinct clinically
relevant disease phenotypes were represented. Finally, the model was shown to be useful for pre-clinical testing of
therapies based upon molecular targets and dose-effect relationships.
Conclusions/Significance: Our work illustrates a dynamic computer simulation of granulomatous inflammation scenarios
that is useful for the investigation of disease mechanisms and for pre-clinical therapeutic testing. In lieu of relevant in vitro or
animal surrogates, our model may provide for the screening of potential therapies for specific sarcoidosis disease
phenotypes in advance of expensive clinical trials.
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Introduction
Sarcoidosisisachronicgranulomatousdiseaseofunknowncause,
for which relevant research models are lacking. Human research in
sarcoidosis is hindered by the existence of diverse clinical
phenotypes, presumably relating to genetic and environmental
variables [1]. Genetic variability may also explain the unpredictable
response to treatment among sarcoidosis patients [1]. Given the
genetic diversity of the disease, environmental variables (e.g.,
antigen exposures) and the lack of relevant animal models, it would
be necessary to recruit large numbers of patients, at a substantial
cost, to represent all of the sarcoidosis phenotypes using
conventional clinical research approaches. Alternatively, new
generation, high-throughput genetic screening platforms provide
an unprecedented opportunity to stratify the molecular basis of
sarcoidosis disease phenotypes with the ultimate goal of individu-
alizing therapy. To this end, it will be necessary to determine how
genetic variability influences disease pathogenesis and treatment.
In this report, we focus on sarcoidosis phenotypes that are
suspected to arise from defective antigen-dependent Th1 type
immune responses associated with deregulated interactions among
essential immune cells such as T effector cells, T regulatory cells,
and antigen-presenting macrophages. The interactions among
these cells are mediated by cytokines such as IL-2, IFNc, and
TNFa. We hypothesized that this complex interaction network
contained sufficient information for the investigation of ‘‘normal’’
and ‘‘sarcoidosis-like’’ Th1 responses to antigens. Thus, we
developed a computational model to represent the dynamics of
this interaction network and its responses to perturbations. Our
results are the first demonstration of an in silico model of
granulomatous inflammation with potential applications for
mechanistic and therapeutic research relating to sarcoidosis and
other related diseases.
Results
A minimal model for Th1 activation
The hallmark of sarcoidosis is the preponderance of Th1
immune response to poorly characterized antigens. The differen-
tiation of naive T cells upon antigen presentation and polarizing
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modeling (see, for example, Yates et al. [2], Mariani et al. [3],
and Mendoza et al. [4]). To cope with the complexity of the
immune network, we first simplified these models to a minimal
model that captures Th1 activation characterized by a bistable
switch, as these previous models have shown. The following
equation can describe this bistable switching behavior (without
explicitly considering interactions with other immune cells for
now):
d
dt
T~bTz
fTT2
hTzT2

{eTT ð1Þ
Note that we are interpreting T as Th1 activity or the density of
CD4+ T effector cells (Teffs) with the Th1 phenotype. The first
and last terms on the right-hand side of this equation set the net
basal flux (influx rate, bT, minus the clearance rate, eTT) of Teffs in
the system. These terms give the basal steady state level of T equal
to bT/eT. The rate of Th1 activation is assumed to be given by the
Hill-type function in the second term of Eqn 1. This sigmoidal
function represents the autocatalytic increase in Th1 activity after
antigen presentation and subsequent autocrine cytokine signaling
which occurs for positive values of fT. As will be shown in the next
subsection, the factor fT links Teffs to the influence of antigens (of
density A) and cytokines (of density c); for now we use the following
equation:
fT~g1Azg2c ð2Þ
where g1 and g2 are non-negative coefficients.
Supplementary information, represented by Eqn S1 and
Figure S1 (see Text S1), proves that Eqn 1 gives rise to a bistable
range of fT; in other words, within this range of fT, the system
can be at low or at high Teff steady state activities, and which
state is achieved depends on the initial conditions of the system.
This bistability predicts that as fT is increased from a low value,
there is a threshold value of fT where there occurs a
discontinuous switch to high Th1 activity. In other words,
sufficient increase in antigen and/or cytokine densities can bring
about a sharp transition to high Teff steady state (Ts) levels.
Alternatively, the system can switch to the upper branch of
steady states within the bistable range by perturbing T so that its
value crosses the middle branch of the curve. This is illustrated
in Figure 1 where a square pulse of A is applied to the system,
and a pulse of sufficient amplitude succeeds in switching the
system to a larger Ts.
Regulatory T cells (Tregs) are expected to increase the threshold
for achieving high steady state T activity. As per Eqn 1, an
increase in the value of the parameter hT in this simple model
corresponds to an increase in Treg density in the detailed model
discussed in the next subsection. This relationship is schematically
represented in Figure S1 (see Text S1), wherein the effect of
greater Treg activity (hT) is to increase the value of fT where the
switch to high Ts activity occurs – that is, the antigen or cytokine
threshold for promoting high-level Teff activity is increased.
A model involving essential components of granulomas
(Teffs, Tregs, and macrophages)
Here, we present a network model that involves the interactions
of Teffs with macrophages and Tregs. The predisposition to
sarcoidosis has implicated some dysfunction of naturally occurring,
innate, Tregs [4]. Macrophages are also essential in the model
because, first, they are known to be highly recruited by active Teffs
to become part of granulomas (they represent the bulk of the
granuloma by mass), macrophages synergize with Teffs in the
secretion of IFNc and TNFa, and macrophages interact with and
affect Treg activity [5–9]. The model immune network shown in
Figure 2A minimally depicts the essential interactions among
Teffs, Tregs, macrophages, and key cytokines secreted by these
cells that mediate cell-cell interactions, namely, IL-2, IFNc and
TNFa. As in the previous section, this model is phenomenological
in that it does not include all known mechanistic details but rather
captures the qualitative dynamics of the interactions among the
players of the system – that is, how one player promotes or inhibits
the densities or activities of other players in the network. Figure 2B
summarizes the net interactions between cells in a so-called
qualitative network (qNET), as we described previously [10]. As will
be demonstrated in the next section, this qNET is useful to guide
our intuition on the potential dynamics of the detailed model of
Figure 2A.
For the model in Figure 2A, the rate of change of T is described
by:
d
dt
T~bTz
fTT2
hTzT2zk1dR

{k1eaT{eTT
ð3Þ
where fT~k1aAMzk1bdzk1cc
A, M, d and c are densities of antigens, macrophages, IL-2 and
IFNc, respectively. Note that the product AM represents antigen
presentation to Teffs by macrophages. We assume that macro-
phages are the only antigen-presenting cells, and increasing M
leads to increased antigen presentation to Teffs.
There are several mechanisms by which Tregs antagonize the
activity of Teffs [9,11], but we subsume all these mechanisms in
the inhibitory effect of Tregs on the proliferation of Teffs as
implemented by including k1dR in the denominator of the second
term on the right-hand side of Eqn 3. Thus, the downregulation by
Tregs of the production of IL-2, IFNc and TNFa is indirectly
caused by the inhibition of Teff proliferation.
The following equations for the rates of change in the densities
of Tregs (R) and macrophages (M) can be understood from the
interactions shown in Figure 2:
d
dt
R~bRz
fRR2
hRzR2

{k2baR{eRR ð4Þ
where fR~k2ad
d
dt
M~bMz
fMM2
hMzM2zk6bR

{eMM ð5Þ
where fM~k6czk6ca
Also, looking at Figure 2, the rates of change in the densities of the
cytokines can be described by the following differential equations:
d
dt
d~bdzk3T{edd ð6Þ
d
dt
c~bczk4aTzk4bM{ecc ð7Þ
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dt
a~bazk5aTzk5bM{eaa ð8Þ
Equations (3)–(8) form the complete set of ordinary differential
equations that describe the dynamics of our model (see Figure S2).
Potential dynamics from the qNET structure
The qNET shown in Figure 2B summarizes the qualitative
interactions between pairs of immune cells. This qNET can
already give us some intuition as to what to expect for the long-
term states of the system. Arrows mean ‘‘activate’’ or upregulate,
while hammerheads mean ‘‘inhibit’’ or downregulate. Without
Tregs, it is obvious that Teffs and macrophages synergize and
activate each other, but only to a point where high levels of TNFa
(a by-product of this synergy) are sufficient to suppress Teffs [this
regulatory activity of macrophages towards Teffs has been
suggested by Nagar et al [12] (see below)]. Without this
macrophage-dependent suppression of Teffs, and without Tregs,
a runaway immune response (unchecked activation and prolifer-
ation of Teffs and macrophages) is predicted.
Tregs exert suppressive activities on both Teffs and macro-
phages, as depicted through edges b and f, respectively. The solid
black circle at the end of edge a is initially an arrow (activation)
representing the IL-2-dependent activation of Tregs by Teffs [13].
However this arrow may turn into a hammerhead (suppression) if
the negative effects of TNFa (whose levels are also induced by
Teffs) begin to dominate [12]. With edge a being an arrow, the
pair of edges a and b is a negative feedback loop that could lead to
an oscillation between the numbers of Teffs and Tregs (this
oscillation could be damped or sustained, as previous mathemat-
ical modeling, and experimental observations, have shown
[14,15]. If edge a is a hammerhead, a toggle switch (mutual
inhibition) could ensue; in other words, either Tregs annihilate
Teffs or vice versa. Note that the interactions between Tregs and
macrophages are also assumed to constitute a toggle switch (edges
e and f), based upon established mechanisms [16,17].
Figure 1. Bistable switching behavior of effector T cell (T) response. A simple model of the response of effector T cells to antigens and
cytokines predicts a threshold of antigen level that triggers a Th1 immune response (see Eqns 1 and 2). T in Eqn 1 is interpreted as Th1 activity. A
square pulse of antigen with amplitude A1=3.5 (applied from t=5 to t=10) fails to increase T, while increasing the amplitude to A2=4 leads to a
rapid increase in Th1 activity at the level T2. Parameters: hT=1,bT=0.02, eT=1,c=3,g1=g2=1, initial T=0.34.
doi:10.1371/journal.pone.0019544.g001
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macrophages as predicted by the qNET of Figure 2B? Using only
a rough characterization of cellular levels (low and high,
symbolized by 0 and +, respectively), not all of the 8 possible
states can be realized due to the structure of the qNET, as shown
in Table 1.
The ‘healthy state’’ (state 1) is characterized by very low or non-
existent levels of Teffs, Tregs and macrophages. Possible ‘‘sarcoid
states’’ are states 5–8, although state 5 is predicted to be unlikely
from the qNET structure alone (because macrophages go up with
Teffs in the absence of Tregs which is the only source of inhibition
according to the qNET). Note that states 6 and 7 involve
simultaneous high activities of Th1 and Tregs which, as will be
explained in the next section, explains the immune paradox
discussed by Miyara et al [4].
The important question that modeling hopes to contribute is
to predict the possible scenarios on how a healthy state switches
to a sarcoid state. For this, we need to perform computer
dynamic simulations of the full model. The base parameters
used for the detailed model (depicted in Figure 2A) are provided
in Table 2.
Thresholds of sarcoidosis (Th1 activation) related to
amplitude of antigen exposure
The typical immune response to a single antigen exposure is
self-limited. However, antigen exposures of sufficient duration or
amplitude are capable of inducing a new steady state characterized
by dramatic expansion of immune cell populations along with
sustained increases in pro-inflammatory cytokines (Figure 3). This
scenario would correspond to persistent granulomatous inflam-
mation (active sarcoidosis).
Switching behavior of Treg levels due to sensitivity to
IL-2
Tregs are considered to be important determinants of
granulomatous inflammation in patients with sarcoidosis [5,18].
Based upon our modeling assumptions (Figure 2A) and previous
reports [15,19], it would appear that Treg activity is critically
dependent upon IL-2. Figure 4 confirms that steady state level of
Tregs sensitively depends on the parameter k2a (which is the
coefficient of the dependence of Treg proliferation on IL-2).
Figure 4B corresponds to state 8 in Table 1, wherein Tregs are
elevated along with Teff and macrophages. This represents the
clinical scenario wherein active pulmonary sarcoidosis is paradox-
ically associated with anergy to new antigens (i.e., suppression by
Tregs) [4].
Modeling therapeutic interventions
Assuming no change in Treg sensitivity, as modeled in Figure 4,
we sought to determine the effects of suppression of either IL-2 or
IFNc levels (corresponding to anti-IL-2 or anti- IFNc therapy).
As shown in Figure 5, ‘‘monotherapy’’ with either anti-IL-2 or
anti- IFNc is capable of suppressing Treg and macrophage
activation, respectively, without affecting high steady-state
activation of Teff cells. In contrast, Figure 6 shows that
combinations of anti-IL-2 and anti- IFNc at appropriate ‘‘doses’’
(as represented by the amplitude of inhibition) maintains all cell
lines in the low steady-state activation state following antigen
Figure 2. Modeling assumptions for Th1 responses. (A) The detailed immune network model involving Th1 activity (T), Tregs (R), and
macrophages (M), with their interactions mediated by the cytokines IL-2, IFNc, and TNFa. Arrows mean ‘‘upregulate’’ or activate while hammerheads
mean ‘‘downregulate’’ or inhibit. A refers to the antigen presented by M to activate T. (Fig S2 in the Appendix shows a version of the network that
corresponds to the differential equations of the model.) (B) A qualitative network (qNET) summarizing the pairwise interactions between the immune
cells. Arrows ending with solid black circles represent either activation or inhibition. The edges a-f are explained in the text.
doi:10.1371/journal.pone.0019544.g002
Table 1. Long-term states predicted by the qNET shown in
Figure 2B.
TR M
state 1 : healthy (Figs 3A, 6B, 6C) 0 0 0
state 2 : unlikely 0 + 0
state 3 : unlikely 0 0 +
state 4 :unlikely 0 ++
state 5 :unlikely + 00
state 6 : sarcoid, lymphopenia (Fig 5D) ++ 0
state 7 : sarcoid (Figs 4A, 5B, 6A, 6E) + 0 +
state 8 : sarcoid, lymphopenia (Figs 3C,
4B, 5A, 5C, 6D, 6F, 7A)
++ +
Zero (0) and plus (+) mean low and high values, respectively. Figure numbers
under column 1 refer to examples found in simulations of the detailed model.
doi:10.1371/journal.pone.0019544.t001
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modeling conditions accurately depict the mechanisms regulating
granuloma formation in the setting of sarcoidosis, careful titration
of combination therapy with anti-IL-2 and anti-IFNc is predicted
to effectively attenuate disease activity.
Anti-TNFa therapy can promote the sarcoidosis
phenotype
Considering that sarcoidosis is a polygenic disease with diverse
phenotypes, models must be adjusted to represent each disease
phenotype. Whereas anti-TNFa therapy often suppresses sarcoid-
Table 2. Base parameter values used for the detailed model in Fig. 2A (see also Fig. S2).
Initial Conditions T=0.01 R=0.01 M=0.001 d=0.001 c=0.001 a=0.001
Teff (T) bT=0.05 eT=1.0 hT=1.0 k1a=1.0 k1b=20.5 k1c=10.0 k1d=1.0 k1e=0.1
Treg (R) bR=0.05 eR=1.0 hR=1.0 k2a=1.0 k2b=0.1
Macrophage (M) bM=0.05 eM=1.0 hM=1.0 k6=1.0 k6b=1.0 k6c=0.1
IL-2 (d) bd=0.01 ed=10.0 k3=1.0
IFNc (c) bc=0.01 ec=10.0 k4a=1.0 k4b=1.0
TNFa (a) ba=0.01 ea=10.0 k5a=1.0 k5b=1.0
doi:10.1371/journal.pone.0019544.t002
Figure 3. Antigen-dependency of Th1 activity. The detailed model of Fig 2A predicts thresholds of antigen level or duration that trigger Th1
activity. Shown in this figure are the dynamics of the model variables at pre- and post-threshold duration of antigen exposure. The system is first
allowed to reach the low steady states of all variables, and then exposed to a square pulse of antigen (with amplitude A=100) from t=20 to t=69 (A
and B) or from t=20 to t=70 (C and D) as indicated by the arrows on the abscissa. All parameters as in Table 2, except k2a=2.1.
doi:10.1371/journal.pone.0019544.g003
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actually promoted by anti-TNFa therapy [22,23]. In this regard, it
is interesting that the current model assumptions predict that
monotherapy with anti-TNFa would either be ineffective or could
paradoxically promote the sarcoidosis state (Figure 7).
Discussion
In silico modeling of lung disease is in its infancy, as reflected by
the few published attempts to date, particularly relating to lung
physiology [24,25]. However, leading scientific organizations like
the National Institutes of Health (NIH) anticipate the need for in
silico modeling to accommodate the exponential growth of
information emerging from human genetic studies. With respect
to strategic planning towards the goal of providing ‘‘personalized
medicine’’ based upon genetic profiling, the NIH seeks to ‘‘use in
silico and statistical modeling/simulation strategies to design and
inform genetic/pharmacogenetics clinical trials, so results can
eventually be used for tailoring treatment or prevention’’ (http://
www.nhlbi.nih.gov/about/dcvd/sp/dcvd-sp-goal-1.1.htm). The in
silico sarcoidosis model presented here possesses relevant features,
including representation of ‘‘normal’’ and ‘‘disease’’ phenotypes,
and the capacity to perform preclinical therapeutic testing. As
such, this model serves as a promising template for future
sarcoidosis research.
Based upon putative interactions among critical components
essential for granuloma formation, our model demonstrates that
a biphasic immune response is expected depending on the
Figure 4. Sensitivity of Tregs (R) to the parameter k2a (response to IL-2). The system is first allowed to reach the low steady states of all
variables, and then exposed to a square pulse of antigen (with amplitude A=100) from t=20 to t=70 as indicated by the arrows on the abscissa. All
parameters as in Table 2, except k2a which when increased above a specific threshold (compare Panel A vs Panel B) promotes a dramatic increase in
Tregs.
doi:10.1371/journal.pone.0019544.g004
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suppression of Treg function, as was demonstrated in the lungs
of sarcoidosis patients [4] presumably in response to TNFa [9],
is sufficient to reduce the threshold for a sustained antigen-
dependent Th1 response. In lieu of an altered immune response
(i.e., normal host), the model further predicts that a sarcoidosis-
like Th1 response could be elicited by an antigen challenge of
sufficient intensity. This model behavior is consistent with a
number of clinical reports of previously healthy patients
developing sarcoidosis following a single, massive antigen
exposure, such as the case in first-responders to the 9/11
disaster in New York City [26,27].
To the extent that the computational model represents
mechanisms predisposing to unregulated granuloma formation
in the context of sarcoidosis, various ‘‘treatments’’ can be
simulated by mathematically manipulating one or more of the
extracellular immunomodulating molecules. This approach is
illustrated in Figures 5, 6 and 7, wherein suppression of any
single molecule (IL-2, IFNc or TNFa)f a i l st od e c r e a s eT e f f
density in the sarcoidosis phenotype, whereas simultaneous
suppression of IL-2 and IFNc restores the system to the baseline
s t a t e( i . e . ,d i s e a s er e m i s s i o n ) .T h e s er e s u l t sa r es t r o n g l y
dependent on the modeling assumptions, including the func-
tional status of specific components of the network, as
represented by changes in the kinetics or the character
(inhibition, activation) of the interactions of one or more of
the components in Eqns 3–8. A key feature of our model is that
it conveniently allows for adjustments to accommodate diverse
disease mechanisms. As a specific example, the sarcoidosis-
associated BTNL2 mutation which results in a truncation
mutation of the BTNL2 protein, a B7-family protein predicted
to inhibit interactions between antigen-presenting cells and
Teffs [28], would be represented by an increase in fT in Eqn 3.
This would have the same effect as diminishing Treg function
(hT, Eqn 3) in that the threshold for achieving the high Ts would
be reduced, favoring the sarcoidosis phenotype.
Figure 5. Single therapies using anti-IL2 (Id) or anti-IFNg (Ic). The system is first allowed to reach low steady states of all variables, and then
exposed to a square pulse of antigen (with amplitude A=100) from t=20 to t=70 to obtain a sarcoid state. As shown in (A) and (B), the model
predicts that there is a threshold of anti-IL2 (between amplitudes Id=29 and Id= 30) that will push the steady state of R to a low level, but not T and
M. The anti-IL2 therapy is represented by asquare pulse of Id given between t=100 and t=120. And as shown in (C) and (D), the model also predicts
that there is a threshold of anti-IFNc (between amplitudes Ic=15 and Ic=16) that will push the steady state of M to a low level, but not T and R. The
anti-IFNc therapy is represented by a square pulse of Ic given between t=100 and t=150. All parameters as in Table 2, except k2a=2.1.
doi:10.1371/journal.pone.0019544.g005
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paradox discussed by Miyara et al [4], wherein excessive antigen-
mediated inflammation in the lungs coexists with impaired antigen
responsiveness (anergy) elsewhere. Recent studies suggest that
expansion of Tregs at the sites of active granulomatous tissue
inflammation causes suppression of T cell proliferation elsewhere,
leading to peripheral lymphopenia and anergy, which are well-
documented manifestations of active pulmonary sarcoidosis
[29,30]. This scenario is represented by conditions 6 and 8 in
Table 1, and Figures 4B, 5C, 6D, 6F, 7C.
Admittedly, our model is incomplete in that detailed informa-
tion relating to the actual kinetics and functions of the system
Figure 6. Combination therapies using anti-IL2 and anti-IFNc. The system is first allowed to reach low steady states of all variables, and then
exposed to a square pulse of antigen (with amplitude A=100) from t=20 to t=70 to obtain a sarcoid state. For (A)-(C), k2a=2.0. Combinations of
anti-IFNc (Ic) and anti-IL2 (Id) are applied as square pulses at the same time, between t=100 and t=120. The combination in (A) is not successful,
while those of (B) and (C) are successful in pushing down the levels of T and M (although there is a slight increase in R compared to its level in (A), R is
still very low). For (D)–(F), k2a=2.1. An increase in anti-IL2 (Id) from 29 to 40 brings down R, but not T and M. Note that a small addition of Ic as shown
in (F) returns R to the high steady state level. All parameters as in Table 2, except k2a.
doi:10.1371/journal.pone.0019544.g006
Figure 7. Single therapy using anti-TNFa (Ia). The system is first allowed to reach low steady states of all variables, and then exposed to a
square pulse of antigen with amplitude A=100 from t=20 to t=70 (indicated by the first two black arrows from the left) to obtain a sarcoid state. (A)
Without anti-TNFa (Ia=0). (B) Anti-TNFa is introduced as a square pulse with amplitude Ia=21.1 from t=100 to t=140 (indicated by the last pair of
thick gray arrows); (C) Anti-TNFa is introduced as a square pulse with amplitude Ia=21.2 from t=100 to t=140 (indicated by the last pair of thick gray
arrows). All parameters as in Table 2, except k2a=2.1 and k2b=0.2.
doi:10.1371/journal.pone.0019544.g007
In Silico Model of Sarcoidosis
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molecules are not considered. For instance, recruitment of macro-
phages induced by IL-2 is not included in model [31] and many cells
and cytokines involved in granuloma formation (e.g., natural killer T
cells, a/d T cells, IL-12, IL-23 [8,32]) are not considered.
Nonetheless, the qualitative framework of the model is adaptable as
more details relating to mechanisms of granuloma formation and
disease pathogenesis emerge, including the effects of genetic
variability. Moreover, model simulations are convenient in that they
can be run using inexpensive and readily-available computational
facilities, as well as practical in that they accurately portray relevant
clinical phenotypes, even in the simplified form presented herein.
In summary, we provide the first dynamic computer simulation
of granuloma formation in sarcoidosis, a disease for which relevant
in vitro or animal models do not currently exist. The qualitative
network is shown to accurately model distinct disease mechanisms,
including a sarcoidosis state resulting from either massive antigen
exposure or altered immune (e.g., Treg) function, and specific
sarcoidosis phenotypes (e.g., lymphopenic sarcoidosis). The model
demonstrates the capacity for pre-clinical therapeutic testing, and
adaptability based upon distinct disease immunophenotypes, such
as those dictated by genetic variability.
Methods
To determine the steady states of the detailed model, the
baseline values for each parameter was set to the values shown in
Table 2 and further modified, as described for each experimental
condition, and the corresponding systems of differential equations
(Eqns 3–8, above) were solved numerically using the BerkeleyMa-
donna software (http://berkeleymadonna.com).
Supporting Information
Figure S1 Steady state of T (Ts) as a function of fT (from
Eqn 2) for two values of hT( hT=1 for the black curve,
and hT=0.5 for the gray curve). Other parameter values:
bT=0.05, eT=1.
(TIF)
Figure S2 The detailed immune network model, show-
ing numbered interactions representing the model
differential equations for each cell [T effector (T), Treg
(R), Macrophage (M)] or molecule (TNFa, IFNc, IL-2),
represented by Eqns 3–8. Arrows mean ‘‘upregulate’’ or
activate while hammerheads mean ‘‘downregulate’’ or inhibit.
(TIF)
Text S1 Supporting information demonstrating a bis-
table switch between low and high Teff steady states
predicted by the model.
(DOC)
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